



NDA 19-357/S-014

Questcor Pharmaceuticals, Inc.
Attention: Matthias C. Kurth
Acting Vice President, Clinical Research and
Regulatory Affairs
2714 Loker Avenue West
Carlsbad, CA 92008

Dear Dr. Kurth:

Please refer to your supplemental new drug application dated January 16, 2002, received January 17, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Ethamolin® (ethanolamine oleate) Injection, 50 mg/mL.

This supplemental new drug application provides for changes to the HOW SUPPLIED section of the currently approved package insert as well as changes to the carton and immediate container labeling.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, this application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert, immediate container, and carton labeling submitted January 16, 2002).

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed, to your application. Please mount individually ten of the copies on heavy-weight paper or similar material. Alternatively, you may submit the FPL electronically according to the guidance for industry titled, *Providing Regulatory Submissions in Electronic Format – NDAs* (January 1999). For administrative purposes, this submission should be designated, "FPL for approved supplement NDA 19-594/S-014". Approval of this submission by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Brian Strongin, R.Ph., M.B.A. at (301) 827-7310.

Sincerely,

{See appended electronic signature page}

Victor F.C. Raczowski, M.D., M.Sc.
Acting Director
Division of Gastrointestinal and
Coagulation Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Joyce Korvick
2/5/02 01:17:23 PM